Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options

1
Non-Hodgkin Lymphoma Therapeutics in Major
Developed Markets to 2020 - New Entrants and
Promising Pipeline Widen Targeted and
Immunotherapeutic Treatment Options
Single User License - 4995 Site User
License - 9990 Corporate User License -
14985 Publication Date - Oct 2014 Pages -
109 To know more details, email to
debora_at_reportstack.com
2
Summary

• This report provides in-depth insight into the
  indication. It provides estimates of market size
  for 2013 along with forecasts until 2020 for the
  eight major developed markets, which comprises
  the US, UK, France, Germany, Italy, Spain, Japan
  and Canada. It also covers disease epidemiology,
  treatment algorithms, treatment patterns,
  in-depth analysis of clinical trials including
  failure rates and pipeline analysis, and analysis
  of deals relevant to Non-Hodgkin Lymphoma (NHL).
• The value of the NHL market is expected to reach
  9.2 billion by 2020 from 5.6 billion in 2013 at
  a modest Compound Annual Growth Rate (CAGR) of
  7.4. The expected launch of promising drugs,
  including novel small molecule inhibitors and
  next-generation monoclonal antibodies, as well as
  the continued use of the current blockbuster,
  Rituxan/Mabthera (rituximab), will be the key
  growth drivers.

3
Scope

• A brief introduction to NHL, including the
  diseases pathogenesis, etiology, diagnosis and
  treatment algorithms
• In-depth analysis of currently marketed drugs for
  NHL, examining their safety, efficacy, treatment
  patterns and strengths/weaknesses and including a
  heat map that compares the drugs in terms of
  safety and efficacy
• A comprehensive review of the pipeline for NHL,
  including individual analysis of a number of
  late-stage pipeline drugs that are likely to
  enter the market during the forecast period the
  pipeline is analyzed on the basis of Phase
  distribution, molecule type, program type,
  mechanism of action and molecular target
• Additional in-depth analysis of pipeline drug
  clinical trials by Phase, trial size, trial
  duration and program failure rate for each
  molecule type

4
Key Benefits

• Understand the NHL pipeline and the factors that
  indicate that it is becoming more innovative
• Examine detailed profiles of promising pipeline
  products and gain an insight into how they are
  likely to compete in the market and who their
  main competitors will be
• Follow the trends in NHL clinical trial size and
  duration in relation to industry averages and
  assess the potential risk of future developmental
  programs according to mechanism of action by
  considering the recorded clinical trial failure
  rates
• Observe the potential growth patterns expected
  for the NHL market over the forecast period,
  identify which countries are expected to make the
  biggest contribution to this growth, and devise a
  more effective country strategy through an
  understanding of key drivers and barriers in the
  NHL market

5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com